Ependymoma
What is an ependymoma?
Are ependymomas classified as low-grade (benign) or high-grade (malignant) brain tumours?
Other types of ependymoma
Frequently asked questions
What causes an ependymoma?
Ependymomas develop from ependymal cells, which are a type of glial cell. Glial cells provide the structure around neural cells within the brain, and help to keep the neural cells healthy. When the DNA within an ependymal cell becomes damaged, the cell can replicate itself in an uncontrolled way, without apoptosis. This uncontrolled growth is what leads to the formation of a tumour.
Ependymoma tumours can occur as a result of a genetically inherited condition called neurofibromatosis 2.
What are the symptoms of an ependymoma?
The symtoms of an ependymoma will depend upon where it has arisen in the brain. Find out more here.
What is the best treatment for ependymoma?
Children and adults with ependymoma respond differently to treatment and therefore tend to be treated in different ways.
The first line treatment for both adult and paediatric ependymoma is surgery. For some patients, particularly those for whom the surgery successfully removes the tumour, no further treatment is offered, although close monitoring using regular MRI scans is highly recommended.
For paediatric patients with ependymoma, the surgery is sometimes done in a staged way so that some of the tumour is removed, and then the tumour is shrunk further using radiotherapy, chemotherapy or a combination of both treatments. Another operation may then be undertaken to remove more of the tumour.
For some adult patients, radiotherapy is offered once they have recovered from the surgery.
It is unusual for adults to be offered chemotherapy unless they have a grade 3 ependymoma. It is more common for children to be offered chemotherapy for their ependymoma brain tumour.
How will we find a cure for ependymoma?
Research we are funding across all of our Centres of Excellence will help lead towards finding a cure for a wide range of brain tumours.
Our University of Plymouth Low-Grade Brain Tumour Research Centre of Excellence is Europe’s leading research institution for low-grade brain tumours. The teams there have a strong focus on both Neurofibromatosis 2 and brain tumours that have an NF2 gene mutation.
The team of research and clinical experts at our Brain Tumour Research Centre of Excellence at Imperial College, London, work closely with the University of Plymouth Centre of Excellence on certain aspects of research into low-grade brain tumours, including those with an NF2 gene mutation.
Scientists at our Brain Tumour Research Centre of Excellence in the University of Portsmouth also collaborate with the University of Plymouth Centre of Excellence on some aspects of low-grade brain tumour research. They have developed models of the blood-brain barrier that support research into drug therapies for all types of brain tumours.
Pioneering research at our Brain Tumour Research Centre of Excellence at Queen Mary University of London has developed methods of studying stem cells that could potentially transfer across all types of brain tumour.
We also fund BRAIN UK at Southampton University, the country’s only national tissue bank providing crucial access to brain tumour samples for researchers from the archives of clinical neuroscience centres in the UK, effectively covering about 90% of the UK population, which is an essential component in the fight to find a cure for brain tumours.